Maverick Therapeutics Inc. — Form D
Maverick Therapeutics Inc. of BRISBANE, CA, a company, filed a Form D exempt-offering notice with the SEC on 2017-01-19. The offering totals $56.0M, of which $56.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-01-19
- Form: D
- Accession: 0001695203-17-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $56.0M
- Amount sold: $56.0M
- Investors: 5
- Date of first sale: 2017-01-06
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-278798
Issuer
- Name: Maverick Therapeutics Inc.
- CIK: 0001695203
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 3260B BAYSHORE BOULEVARD, BRISBANE, CA, 94005
- Phone: 650-443-7400
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Christopher Arendt | Director | Brisbane, CA |
| Luke Evnin | Director | Watertown, MA |
| Bard Geesaman | Director | Cambridge, MA |
| Hans Peter Gerber | Director | Brisbane, CA |
| Dan Hicklin | Director | Brisbane, CA |
| Lori Kunkel | Director | San Francisco, CA |
| Hans Peter Gerber | Executive Officer | Brisbane, CA |
More